

**Table DS1 Duloxetine-Venlafaxine Comparison: Demographics and Comorbidities Before and After Propensity Score Matching**

	Duloxetine Unmatched n (%)	Venlafaxine Unmatched n (%)	Duloxetine Matched n (%)	Venlafaxine Matched n (%)
Total N	3028	5538	2629	5493
Demographic/Patient Characteristics				
Age at Index Date (mean, median)	43.11,44.00	41.06,42.00	42.53,43.00	41.02,42.00
Range (minimum, maximum)	(18-98)	(18-98)	(18-97)	(18-98)
Gender (female)	2017 (66.61%)	3744 (67.61%)	1736 (66.03%)	3714 (67.61%)
Medicaid Status	16 (0.53%)	66 (1.19%)	16 (0.61%)	59 (1.07%)
Region				
East	654 (21.60%)	1279 (23.09%)	557 (21.19%)	1277 (23.25%)
Midwest	1199 (39.60%)	2476 (44.71%)	1112 (42.30%)	2452 (44.64%)
South	975 (32.20%)	1387 (25.05%)	778 (29.59%)	1378 (25.09%)
West	200 (6.61%)	396 (7.15%)	182 (6.92%)	386 (7.03%)
Comorbidities				
CDI Score <sup>a</sup> (mean, median)	3.12,3.00	2.38,2.00	3.09,3.00	2.36,2.00
Range (minimum, maximum)	(0-19)	(0-21)	(0-18)	(0-21)
Charlson Comorbidity Score (mean, median)	0.85,0.00	0.63,0.00	0.79,0.00	0.62,0.00
Range (minimum, maximum)	(0-10)	(0-9)	(0-10)	(0-9)
Prior Depression	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Bipolar Disorder/by proxy	9 (0.30%)	28 (0.51%)	9 (0.34%)	26 (0.47%)
Schizophrenia	3 (0.10%)	4 (0.07%)	3 (0.11%)	3 (0.05%)
Psychotic Disorder	21 (0.69%)	29 (0.52%)	20 (0.76%)	28 (0.51%)
Anxiety Spectrum Disorder	202 (6.67%)	399 (7.20%)	176 (6.69%)	393 (7.15%)
ADHD	16 (0.53%)	28 (0.51%)	12 (0.46%)	28 (0.51%)
Substance Use Disorder	140 (4.62%)	187 (3.38%)	114 (4.34%)	183 (3.33%)
Other Mental Health Disorder	117 (3.86%)	194 (3.50%)	97 (3.69%)	190 (3.46%)
No. of Mental Health Disorders (mean, median)	0.17,0.00	0.16,0.00	0.16,0.00	0.15,0.00
Range (minimum, maximum)	(0-4)	(0-5)	(0-4)	(0-5)
Terminal Diagnosis (HIV or malignant neoplasm)	84 (2.77%)	154 (2.78%)	69 (2.62%)	152 (2.77%)

Smoking	12 (0.40%)	16 (0.29%)	8 (0.30%)	16 (0.29%)
Seizure Disorder	24 (0.79%)	32 (0.58%)	22 (0.84%)	30 (0.55%)
Chronic Pain	16 (0.53%)	2 (0.04%)	5 (0.19%)	2 (0.04%)
Headaches (including migraine)	252 (8.32%)	339 (6.12%)	199 (7.57%)	334 (6.08%)
Stress Urinary Incontinence	18 (0.59%)	21 (0.38%)	14 (0.53%)	21 (0.38%)
Fibromyalgia	170 (5.61%)	169 (3.05%)	120 (4.56%)	164 (2.99%)
Diabetic Neuropathy	122 (4.03%)	92 (1.66%)	89 (3.39%)	89 (1.62%)
Low Back Pain / Back Pain	449 (14.83%)	535 (9.66%)	348 (13.24%)	530 (9.65%)

a. CDI score = Children's depression inventory score

**Table DS2 Duloxetine-SSRI Comparison: Demographics and Comorbidities Before and After Propensity Score Matching**

	Duloxetine Unmatched n (%)	SSRI <sup>a</sup> Unmatched n (%)	Duloxetine Matched n (%)	SSRI <sup>a</sup> Matched n(%)
Total N	3028	74,149	3001	8953
<b>Demographic/Patient Characteristics</b>				
Age at Index Date (mean, Range (minimum, Maximum))	43.11,44.00 (18-98)	40.27,40.00 (18-98)	43.01,44.00 (18-97)	43.43,44.00 (18-98)
Gender (female)	2017 (66.61%)	49,062 (66.17%)	2000 (66.64%)	6007 (67.09%)
Medicaid Status	16 (0.53%)	1436 (1.94%)	16 (0.53%)	93 (1.04%)
Region				
East	654 (21.60%)	14,788 (19.94%)	646 (21.53%)	1924 (21.49%)
Midwest	1199 (39.60%)	37,586 (50.69%)	1195 (39.82%)	3522 (39.34%)
South	975 (32.20%)	13,266 (17.89%)	961 (32.02%)	2869 (32.05%)
West	200 (6.61%)	8509 (11.48%)	199 (6.63%)	638 (7.13%)
<b>Comorbidities</b>				
CDI Score <sup>a</sup> (mean, median, Range (minimum, Maximum))	3.12,3.00 (0-19)	3.19,3.00 (1-21)	3.10,3.00 (0-19)	3.08,2.00 (1-18)
Charlson Comorbidity Score Range (minimum, Maximum)	0.85,0.00 (0-10)	0.67,0.00 (0-14)	0.83,0.00 (0-10)	0.81,0.00 (0-14)
Prior Depression	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Bipolar Disorder/by proxy	9 (0.30%)	201 (0.27%)	9 (0.30%)	18 (0.20%)
Schizophrenia	3 (0.10%)	25 (0.03%)	3 (0.10%)	8 (0.09%)
Psychotic Disorder	21 (0.69%)	426 (0.57%)	21 (0.70%)	56 (0.63%)
Anxiety Spectrum Disorder	202 (6.67%)	4,099 (5.53%)	201 (6.70%)	599 (6.69%)
ADHD	16 (0.53%)	337 (0.45%)	16 (0.53%)	45 (0.50%)
Substance Use Disorder	140 (4.62%)	2724 (3.67%)	136 (4.53%)	353 (3.94%)
Other Mental Health Disorder	117 (3.86%)	2342 (3.16%)	113 (3.77%)	302 (3.37%)
No. of Mental Health Range (minimum, Maximum)	0.17,0.00 (0-4)	0.14,0.00 (0-5)	0.16,0.00 (0-4)	0.15,0.00 (0-5)
Terminal Diagnosis (HIV or malignant neoplasm)	84 (2.77%)	1765 (2.38%)	79 (2.63%)	224 (2.50%)
Smoking	12 (0.40%)	255 (0.34%)	12 (0.40%)	31 (0.35%)
Seizure Disorder	24 (0.79%)	505 (0.68%)	23 (0.77%)	59 (0.66%)
Chronic Pain	16 (0.53%)	47 (0.06%)	10 (0.33%)	15 (0.17%)
Headaches (including migraine)	252 (8.32%)	4,691 (6.33%)	247 (8.23%)	688 (7.68%)
Stress Urinary Incontinence	18 (0.59%)	265 (0.36%)	18 (0.60%)	46 (0.51%)
Fibromyalgia	170 (5.61%)	1791 (2.42%)	161 (5.36%)	392 (4.38%)
Diabetic Neuropathy	122 (4.03%)	1365 (1.84%)	117 (3.90%)	293 (3.27%)
Low Back Pain / Back Pain	449 (14.83%)	6336 (8.54%)	436 (14.53%)	1139 (12.72%)

a. Abbreviation: SSRI = Selective serotonin reuptake inhibitor, CDI Score = Children's Depression Inventory score.

**Table DS3 Duloxetine-TCA<sup>a</sup> Comparison: Demographics and Comorbidities Before and After Propensity Score Matching**

	Duloxetine Unmatched n (%)	TCA <sup>a</sup> Unmatched n (%)	Duloxetine Matched n (%)	TCA <sup>a</sup> Matched n (%)
Total N	3028	1146	1064	1064
<b>Demographic/Patient Characteristics</b>				
Age at Index Date (mean, Range (minimum,	43.11,44.00 (18-98)	44.32,45.00 (18-98)	42.08,43.00 (18-81)	44.50,45.00 (18-98)
Gender (female)	2017 (66.61%)	772 (67.36%)	715 (67.20%)	722 (67.86%)
Medicaid Status	16 (0.53%)	31 (2.71%)	11 (1.03%)	23 (2.16%)
Region				
East	654 (21.60%)	243 (21.20%)	239 (22.46%)	233 (21.90%)
Midwest	1199 (39.60%)	511 (44.59%)	503 (47.27%)	467 (43.89%)
South	975 (32.20%)	269 (23.47%)	212 (19.92%)	261 (24.53%)
West	200 (6.61%)	123 (10.73%)	110 (10.34%)	103 (9.68%)
<b>Comorbidities</b>				
CDI Score (mean, median) Range (minimum,	3.12,3.00 (0-19)	4.68,4.00 (2-18)	3.52,3.00 (0-16)	4.60,4.00 (2-18)
Charlson Comorbidity Score Range (minimum,	0.85,0.00 (0-10)	0.92,1.00 (0-9)	0.85,0.00 (0-10)	0.91,1.00 (0-9)
Prior Depression	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Bipolar Disorder/by proxy	9 (0.30%)	9 (0.79%)	4 (0.38%)	9 (0.85%)
Schizophrenia	3 (0.10%)	1 (0.09%)	1 (0.09%)	1 (0.09%)
Psychotic Disorder	21 (0.69%)	7 (0.61%)	9 (0.85%)	5 (0.47%)
Anxiety Spectrum Disorder	202 (6.67%)	62 (5.41%)	58 (5.45%)	55 (5.17%)
ADHD	16 (0.53%)	0 (0.00%)	4 (0.38%)	0 (0.00%)
Substance Use Disorder	140 (4.62%)	52 (4.54%)	44 (4.14%)	44 (4.14%)
Other Mental Health Disorder	117 (3.86%)	50 (4.36%)	43 (4.04%)	47 (4.42%)
No. of Mental Health Disorders Range (minimum,	0.17,0.00 (0-4)	0.15,0.00 (0-4)	0.15,0.00 (0-3)	0.15,0.00 (0-2)
Terminal Diagnosis (HIV or malignant neoplasm)	84 (2.77%)	45 (3.93%)	33 (3.10%)	40 (3.76%)
Smoking	12 (0.40%)	5 (0.44%)	4 (0.38%)	4 (0.38%)
Seizure Disorder	24 (0.79%)	15 (1.31%)	13 (1.22%)	11 (1.03%)
Chronic Pain	16 (0.53%)	3 (0.26%)	2 (0.19%)	1 (0.09%)
Headaches (including	252 (8.32%)	179 (15.62%)	72 (6.77%)	172 (16.17%)
Stress Urinary Incontinence	18 (0.59%)	4 (0.35%)	5 (0.47%)	3 (0.28%)
Fibromyalgia	170 (5.61%)	64 (5.58%)	37 (3.48%)	60 (5.64%)
Diabetic Neuropathy	122 (4.03%)	51 (4.45%)	33 (3.10%)	48 (4.51%)
Low Back Pain / Back Pain	449 (14.83%)	177 (15.45%)	119 (11.18%)	163 (15.32%)

a. Abbreviation: TCA = Tricyclic antidepressant, CDI score = Children's Depression Inventory score.

**Table DS4 Duloxetine-Multiple Antidepressant Comparison: Demographics and Comorbidities Before and After Propensity Score Matching**

	Duloxetine Unmatched n (%)	Multiple AD <sup>a</sup> Unmatched n (%)	Duloxetine Matched n (%)	Multiple AD <sup>a</sup> Matched n (%)
Total N	3028	28,246	2948	8408
<b>Demographic/Patient Characteristics</b>				
Age at Index Date (mean, Range (minimum, Maximum))	43.11,44.00 (18-98)	40.30,41.00 (18-98)	42.91,44.00 (18-97)	42.59,43.00 (18-98)
Gender (female)	2017 (66.61%)	18,491 (65.46%)	1961 (66.52%)	5480 (65.18%)
Medicaid Status	16 (0.53%)	693 (2.45%)	16 (0.54%)	99 (1.18%)
Region				
East	654 (21.60%)	5227 (18.51%)	642 (21.78%)	1720 (20.46%)
Midwest	1199 (39.60%)	14,824 (52.48%)	1188 (40.30%)	3427 (40.76%)
South	975 (32.20%)	5333 (18.88%)	922 (31.28%)	2749 (32.70%)
West	200 (6.61%)	2862 (10.13%)	196 (6.65%)	512 (6.09%)
<b>Comorbidities</b>				
CDI Score <sup>a</sup> (mean, median, Range (minimum, Maximum))	3.12,3.00 (0-19)	3.92,3.00 (0-20)	3.09,3.00 (0-19)	3.62,3.00 (0-19)
Charlson Comorbidity	0.85,0.00	0.78,0.00	0.83,0.00	0.86,0.00
Range (minimum, Maximum)	(0-10)	(0-11)	(0-10)	(0-11)
Prior Depression	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Bipolar Disorder/by proxy	9 (0.30%)	135 (0.48%)	9 (0.31%)	33 (0.39%)
Schizophrenia	3 (0.10%)	6 (0.02%)	3 (0.10%)	3 (0.04%)
Psychotic Disorder	21 (0.69%)	203 (0.72%)	20 (0.68%)	66 (0.78%)
Anxiety Spectrum Disorder	202 (6.67%)	1738 (6.15%)	200 (6.78%)	610 (7.25%)
ADHD	16 (0.53%)	127 (0.45%)	15 (0.51%)	37 (0.44%)
Substance Use Disorder	140 (4.62%)	1395 (4.94%)	136 (4.61%)	447 (5.32%)
Other Mental Health	117 (3.86%)	1102 (3.90%)	112 (3.80%)	364 (4.33%)
No. of Mental Health	0.17,0.00	0.17,0.00	0.17,0.00	0.18,0.00
Range (minimum, maximum)	(0-4)	(0-5)	(0-4)	(0-4)
Terminal Diagnosis (HIV or malignant)	84 (2.77%)	661 (2.34%)	78 (2.65%)	225 (2.68%)
Smoking	12 (0.40%)	106 (0.38%)	12 (0.41%)	28 (0.33%)
Seizure Disorder	24 (0.79%)	164 (0.58%)	23 (0.78%)	55 (0.65%)
Chronic Pain	16 (0.53%)	15 (0.05%)	8 (0.27%)	8 (0.10%)
Headaches (including migraine)	252 (8.32%)	2341 (8.29%)	235 (7.97%)	795 (9.46%)
Stress Urinary Incontinence	18 (0.59%)	113 (0.40%)	16 (0.54%)	56 (0.67%)
Fibromyalgia	170 (5.61%)	953 (3.37%)	151 (5.12%)	475 (5.65%)
Diabetic Neuropathy	122 (4.03%)	679 (2.40%)	114 (3.87%)	328 (3.90%)
Low Back Pain / Back Pain	449 (14.83%)	3301 (11.69%)	420 (14.25%)	1410 (16.77%)

a. Abbreviation: AD = antidepressant, CDI score = Children's Depression Inventory score.

**Table DS5 Duloxetine-Depressed Untreated (No Antidepressant, AD) Comparison: Demographics and Comorbidities Before and After Propensity Score Matching**

	Duloxetine Unmatched n (%)	No AD <sup>a</sup> Unmatched n (%)	Duloxetine Matched n (%)	No AD <sup>a</sup> Matched n (%)
Total N	3028	255,209	237	564
<b>Demographic/Patient Characteristics</b>				
Age at Index Date (mean, Range (minimum,	43.11,44.00 (18-98)	41.94,43.00 (18-98)	44.01,44.00 (18-81)	47.07,48.00 (18-98)
Gender (female)	2017 (66.61%)	165,894 (65.00%)	168 (70.89%)	373 (66.13%)
Medicaid Status	16 (0.53%)	5,438 (2.13%)	4 (1.69%)	4 (0.71%)
Region				
East	654 (21.60%)	75,765 (29.69%)	41 (17.30%)	143 (25.35%)
Midwest	1199 (39.60%)	96,612 (37.86%)	108 (45.57%)	151 (26.77%)
South	975 (32.20%)	61,364 (24.04%)	57 (24.05%)	241 (42.73%)
West	200 (6.61%)	21,468 (8.41%)	31 (13.08%)	29 (5.14%)
<b>Comorbidities</b>				
CDI Score <sup>a</sup> (mean, median) Range (minimum,	3.12,3.00 (0-19)	1.28,0.00 (0-21)	4.35,4.00 (0-16)	1.92,1.00 (0-17)
Charlson Comorbidity Score Range (minimum,	0.85,0.00 (0-10)	0.82,0.00 (0-17)	1.00,1.00 (0-10)	1.57,1.00 (0-11)
Prior Depression	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Bipolar Disorder/by proxy	9 (0.30%)	1493 (0.59%)	1 (0.42%)	5 (0.89%)
Schizophrenia	3 (0.10%)	236 (0.09%)	0 (0.00%)	5 (0.89%)
Psychotic Disorder	21 (0.69%)	1968 (0.77%)	6 (2.53%)	9 (1.60%)
Anxiety Spectrum Disorder	202 (6.67%)	16,458 (6.45%)	13 (5.49%)	65 (11.52%)
ADHD	16 (0.53%)	1452 (0.57%)	0 (0.00%)	4 (0.71%)
Substance Use Disorder	140 (4.62%)	10,711 (4.20%)	7 (2.95%)	48 (8.51%)
Other Mental Health Disorder	117 (3.86%)	10,676 (4.18%)	9 (3.80%)	40 (7.09%)
No. of Mental Health Range (minimum,	0.17,0.00 (0-4)	0.17,0.00 (0-6)	0.15,0.00 (0-2)	0.30,0.00 (0-3)
Terminal Diagnosis (HIV or malignant neoplasm)	84 (2.77%)	8061 (3.16%)	5 (2.11%)	23 (4.08%)
Smoking	12 (0.40%)	931 (0.36%)	0 (0.00%)	6 (1.06%)
Seizure Disorder	24 (0.79%)	2395 (0.94%)	1 (0.42%)	14 (2.48%)
Chronic Pain	16 (0.53%)	325 (0.13%)	1 (0.42%)	42 (7.45%)
Headaches (including	252 (8.32%)	18,943 (7.42%)	17 (7.17%)	72 (12.77%)
Stress Urinary Incontinence	18 (0.59%)	1177 (0.46%)	1 (0.42%)	8 (1.42%)
Fibromyalgia	170 (5.61%)	8171 (3.20%)	10 (4.22%)	84 (14.89%)
Diabetic Neuropathy	122 (4.03%)	6535 (2.56%)	15 (6.33%)	52 (9.22%)
Low Back Pain / Back Pain	449 (14.83%)	25,859 (10.13%)	24 (10.13%)	176 (31.21%)

a. Abbreviation: AD = antidepressant, CDI score = Children's Depression Inventory score.

**Table DS6 Comparison of All Study Cohorts: Demographics and Comorbidities after Propensity Score Matching**

	Duloxetine n (%)	Venlafaxine n (%)	SSRI <sup>a</sup> N (%)	TCA <sup>a</sup> n (%)	Multiple n (%)	Untreated Depression n (%)	GPS <sup>a</sup> n (%)
Total N	3009	5493	8953	1064	8408	564	27,476
<b>Demographic/Patient Characteristics</b>							
Age at Index Date (mean, median)	43.04,44.00	41.02,42.00	43.43,44.00	44.50,45.00	42.59,43.00	47.07,48.00	43.04,44.00
Range (minimum, maximum)	(18-97)	(18-98)	(18-98)	(18-98)	(18-98)	(18-98)	(18-98)
Gender (female)	2005 (66.63%)	3714 (67.61%)	6007 (67.09%)	722 (67.86%)	5480 (65.18%)	373 (66.13%)	17,950 (65.33%)
Medicaid Status	16 (0.53%)	59 (1.07%)	93 (1.04%)	23 (2.16%)	99 (1.18%)	4 (0.71%)	306 (1.11%)
Region							
East	648 (21.54%)	1277 (23.25%)	1924 (21.49%)	233 (21.90%)	1720 (20.46%)	143 (25.35%)	5968 (21.72%)
Midwest	1196 (39.75%)	2452 (44.64%)	3522 (39.34%)	467 (43.89%)	3427 (40.76%)	151 (26.77%)	10,718 (39.01%)
South	966 (32.10%)	1378 (25.09%)	2869 (32.05%)	261 (24.53%)	2749 (32.70%)	241 (42.73%)	8968 (32.64%)
West	199 (6.61%)	386 (7.03%)	638 (7.13%)	103 (9.68%)	512 (6.09%)	29 (5.14%)	1822 (6.63%)
<b>Comorbidities (6 mo prior to index date)</b>							
CDI Score <sup>a</sup> (mean, median)	3.11,3.00	2.36,2.00	3.08,2.00	4.60,4.00	3.62,3.00	1.92,1.00	1.65,1.00
Range (minimum, maximum)	(0-19)	(0-21)	(1-18)	(2-18)	(0-19)	(0-17)	(0-18)
Charlson Comorbidity Score (mean, median)	0.84,0.00	0.62,0.00	0.81,0.00	0.91,1.00	0.86,0.00	1.57,1.00	0.00,0.00
Range (minimum, maximum)	(0-10)	(0-9)	(0-14)	(0-9)	(0-11)	(0-11)	(0-0)
Prior Depression	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Bipolar Disorder/by proxy	9 (0.30%)	26 (0.47%)	18 (0.20%)	9 (0.85%)	33 (0.39%)	5 (0.89%)	136 (0.49%)
Schizophrenia	3 (0.10%)	3 (0.05%)	8 (0.09%)	1 (0.09%)	3 (0.04%)	5 (0.89%)	16 (0.06%)
Psychotic Disorder	21 (0.70%)	28 (0.51%)	56 (0.63%)	5 (0.47%)	66 (0.78%)	9 (1.60%)	72 (0.26%)
Anxiety Spectrum Disorder	202 (6.71%)	393 (7.15%)	599 (6.69%)	55 (5.17%)	610 (7.25%)	65 (11.52%)	635 (2.31%)
ADHD	16 (0.53%)	28 (0.51%)	45 (0.50%)	0 (0.00%)	37 (0.44%)	4 (0.71%)	88 (0.32%)
Substance Use Disorder	140 (4.65%)	183 (3.33%)	353 (3.94%)	44 (4.14%)	447 (5.32%)	48 (8.51%)	515 (1.87%)
Other Mental Health Disorder	116 (3.86%)	190 (3.46%)	302 (3.37%)	47 (4.42%)	364 (4.33%)	40 (7.09%)	675 (2.46%)
No. of Mental Health Disorders (mean, median)	0.17,0.00	0.15,0.00	0.15,0.00	0.15,0.00	0.18,0.00	0.30,0.00	0.08,0.00
Range (minimum, maximum)	(0-4)	(0-5)	(0-5)	(0-2)	(0-4)	(0-3)	(0-6)
Terminal Diagnosis (HIV or malignant neoplasm)	80 (2.66%)	152 (2.77%)	224 (2.50%)	40 (3.76%)	225 (2.68%)	23 (4.08%)	574 (2.09%)
Smoking	12 (0.40%)	16 (0.29%)	31 (0.35%)	4 (0.38%)	28 (0.33%)	6 (1.06%)	52 (0.19%)
Seizure Disorder	23 (0.76%)	30 (0.55%)	59 (0.66%)	11 (1.03%)	55 (0.65%)	14 (2.48%)	113 (0.41%)
Chronic Pain	10 (0.33%)	2 (0.04%)	15 (0.17%)	1 (0.09%)	8 (0.10%)	42 (7.45%)	15 (0.05%)
Headaches (including migraine)	248 (8.24%)	334 (6.08%)	688 (7.68%)	172 (16.17%)	795 (9.46%)	72 (12.77%)	1148 (4.18%)
Stress Urinary Incontinence	18 (0.60%)	21 (0.38%)	46 (0.51%)	3 (0.28%)	56 (0.67%)	8 (1.42%)	105 (0.38%)
Fibromyalgia	164 (5.45%)	164 (2.99%)	392 (4.38%)	60 (5.64%)	475 (5.65%)	84 (14.89%)	512 (1.86%)
Diabetic Neuropathy	118 (3.92%)	89 (1.62%)	293 (3.27%)	48 (4.51%)	328 (3.90%)	52 (9.22%)	418 (1.52%)

Low Back Pain / Back Pain	440 (14.62%)	530 (9.65%)	1139 (12.72%)	163 (15.32%)	1410 (16.77%)	176 (31.21%)	1709 (6.22%)
---------------------------	--------------	-------------	---------------	--------------	---------------	--------------	--------------

a. Abbreviations: GPS = Community-based general population sample, SSRI = Selective serotonin reuptake inhibitor, TCA = Tricyclic antidepressant, CDI score = Children's Depression score.



**Table DS7 The Effect of Study Cohort (Drug or Drug Class) on Suicide Attempt Risk, Estimated Using Unadjusted and Adjusted Multivariate Cox PH Models of Time to Suicide Attempt**

	HR <sup>a</sup>	Unadjusted Model 95% CI <sup>a</sup>		HR <sup>a</sup>	Adjusted Model 95% CI <sup>a</sup>	
<b>Study Group</b>						
Duloxetine		Referent group			Referent group	
Venlafaxine	0.90	0.51	1.57	1.01	0.57	1.77
SSRI <sup>a</sup>	0.95	0.56	1.62	0.89	0.52	1.52
TCA <sup>a</sup>	0.56	0.22	1.41	0.52	0.20	1.31
Multiple AD <sup>a</sup>	<b>3.57</b>	<b>2.21</b>	<b>5.77</b>	<b>3.11</b>	<b>1.92</b>	<b>5.04</b>
Depressed/No AD <sup>a</sup>	2.16	1.00	4.67	1.28	0.55	2.97
GPS	<b>0.12</b>	<b>0.07</b>	<b>0.23</b>	<b>0.17</b>	<b>0.09</b>	<b>0.32</b>
<b>Demographics</b>						
Female				0.95	0.76	1.19
Age group						
Young adult (18-24 yrs.)				<b>3.31</b>	<b>2.54</b>	<b>4.33</b>
Adult (25-64 yrs.)					Referent group	
Older adult (65+ yrs.)				0.76	0.24	2.41
Medicaid				<b>1.77</b>	<b>1.07</b>	<b>2.93</b>
<b>Region</b>						
East					Referent group	
Midwest				2.23	1.83	4.36
South				<b>1.91</b>	<b>1.35</b>	<b>2.72</b>
West				<b>2.83</b>	<b>1.83</b>	<b>4.36</b>
<b>Comorbidities</b>						
CDI score				1.04	0.99	1.08
Depression				<b>1.82</b>	<b>1.30</b>	<b>2.55</b>
Bipolar				<b>2.75</b>	<b>1.97</b>	<b>3.85</b>
Schizophrenia				1.31	0.51	3.35
Psychotic disorder				<b>1.71</b>	<b>1.11</b>	<b>2.62</b>
Anxiety				1.07	0.82	1.41
ADHD <sup>a</sup>				1.07	0.58	1.98
Substance abuse				<b>2.42</b>	<b>1.82</b>	<b>3.22</b>
Other mental health concern				<b>2.04</b>	<b>1.59</b>	<b>2.60</b>
Chronic pain				<b>4.39</b>	<b>1.88</b>	<b>10.25</b>
Headache				1.00	0.75	1.39
Fibromyalgia				0.87	0.60	1.26
Diabetic neuropathy				0.59	0.33	1.07

a. Abbreviations: HR = Hazard ratio, 95% CI = 95% confidence interval, TCA = Tricyclic antidepressant, GPS = Community-based general population sample, AD = Antidepressant, CDI score = Children's depression inventory score, ADHD = Attention deficit hyperactivity disorder, SSRI = Selective serotonin reuptake inhibitor, ADHD = Attention Deficit Hyperactivity Disorder.